ID

14959

Description

Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01444716

Link

https://clinicaltrials.gov/show/NCT01444716

Keywords

  1. 5/9/16 5/9/16 -
Uploaded on

May 9, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Advanced Cancers NCT01444716

Eligibility Advanced Cancers NCT01444716

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
Description

chronic lymphocytic leukemia

Data type

boolean

Alias
UMLS CUI [1]
C0023434
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
Description

ecog

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
Description

adequate renal and hepatic function

Data type

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0232741
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
Description

prolymphocytic leukemia

Data type

boolean

Alias
UMLS CUI [1]
C0023486
known positivity for hiv
Description

hiv

Data type

boolean

Alias
UMLS CUI [1]
C0019682
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
Description

hepatitis b

Data type

boolean

Alias
UMLS CUI [1]
C0019163
prior treatment for chronic lymphocytic leukemia
Description

chronic lymphocytic leukemia

Data type

boolean

Alias
UMLS CUI [1,1]
C0023434
UMLS CUI [1,2]
C1514463
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
Description

concurrent chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C3178775
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
Description

Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
any known hypersensitivity to ofatumumab or its components.
Description

any known hypersensitivity to ofatumumab or its components.

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1832027

Similar models

Eligibility Advanced Cancers NCT01444716

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
chronic lymphocytic leukemia
Item
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
boolean
C0023434 (UMLS CUI [1])
ecog
Item
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
boolean
C1520224 (UMLS CUI [1])
adequate renal and hepatic function
Item
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
boolean
C0232804 (UMLS CUI [1,1])
C0232741 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
prolymphocytic leukemia
Item
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
boolean
C0023486 (UMLS CUI [1])
hiv
Item
known positivity for hiv
boolean
C0019682 (UMLS CUI [1])
hepatitis b
Item
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
boolean
C0019163 (UMLS CUI [1])
chronic lymphocytic leukemia
Item
prior treatment for chronic lymphocytic leukemia
boolean
C0023434 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
concurrent chemotherapy
Item
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
boolean
C3178775 (UMLS CUI [1])
Protocol Compliance
Item
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
any known hypersensitivity to ofatumumab or its components.
Item
any known hypersensitivity to ofatumumab or its components.
boolean
C0020517 (UMLS CUI [1,1])
C1832027 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial